Placeholder Image

Subtitles section Play video

  • The following content is provided under a Creative

  • Commons license.

  • Your support will help MIT OpenCourseWare

  • continue to offer high-quality educational resources for free.

  • To make a donation or view additional materials

  • from hundreds of MIT courses, visit MIT OpenCourseWare

  • at ocw.mit.edu.

  • ELIZABETH NOLAN: We're going to move on with GroEL/GroES

  • and a few more comments about where we closed yesterday

  • and then talk about experiments that

  • were done to determine what polypeptides

  • are folded by this machinery.

  • So I'm just curious.

  • Has anyone stuck trigger factor or GroEL into PubMed

  • to see how many hits you get?

  • Yeah, so Rebecca's question yesterday, or on Monday,

  • about trigger factor and active versus passive folding

  • motivated me to take a look.

  • So just to give you some scope, if you

  • put trigger factor in PubMed, as of last night,

  • there's 11,810 hits there.

  • GroEL is closer to 2,000 to 3,000-- in that range.

  • If you put trigger factor active folding,

  • you end up with 34 hits.

  • Most of those are about using trigger factor

  • in protein overexpression.

  • So if you also express trigger factor, does that help?

  • And it looked like there was one paper in those 34

  • that suggests an active folding role for one of the domains.

  • But that is just looking at an abstract.

  • And so, the point there is there are many, many studies that

  • consider these chaperones and a huge literature to search.

  • So what we're able to cover here is really just the tip

  • of the iceberg for that.

  • There's also a new review out on GroEL/GroES,

  • which is not required reading, but we're

  • posting it on Stellar.

  • So it just came out last month, and I really

  • enjoyed reading this review.

  • I thought they did a very good job

  • of talking about current questions that are unanswered

  • yet in terms of models and presenting different models

  • for how this folding chamber works-- so passive

  • versus active, for instance.

  • And they also give a summary of the substrate scope--

  • so the experiment we'll talk about today.

  • So where we left off last time, we

  • went over the structure of this folding chamber

  • and here's just another depiction of the overview.

  • So effectively, we have to back-to-back heptamer rings

  • as shown here.

  • Some polypeptide in its non-native state can bind.

  • It initially binds up at the top by these apical domains,

  • and there are some hydrophobic interactions.

  • OK, ATP also binds, and we have all seven ATPs

  • found within one ring, the ring that has the polypeptide.

  • OK, we see the lid come on, and then this polypeptide

  • has some time, a residency time, in this chamber to fold.

  • And then after the residency time,

  • which is generally quoted on the order of 6 to 10 seconds,

  • the lid comes off, and it gets ejected.

  • And during that time, the ATPs are hydrolyzed.

  • So somehow, this ATP hydrolysis gives conformational changes

  • that drive this cycle.

  • OK, and then we see, again, we flip

  • to having function in the other ring.

  • So one point to make involved cooperativity,

  • so I hope you've all seen cooperativity before, probably

  • in the context of hemoglobin.

  • We have examples here of positive cooperativity

  • and negative cooperativity.

  • So within one heptamer ring, ATP binds to all seven subunits.

  • So that's positive cooperativity.

  • And then we can think about negative cooperativity

  • between the two rings, where we only

  • have ATPs bound to one ring.

  • So the other heptamer ring will not have ATP bound here.

  • So what is happening inside this chamber?

  • The polypeptide enters the chamber,

  • and it's given this protected environment to fold.

  • And we saw that when the GroES lid comes in

  • that the hydrophilic nature, hydrophobic nature

  • of the interior changes.

  • And it becomes more hydrophilic.

  • So I just want to point out-- and this also builds upon

  • Rebecca's question from last time--

  • is this passive folding in the chamber

  • so effectively in Anfinsen's cage,

  • where the primary sequence dictates the trajectory?

  • Or does the actual chamber itself play a role?

  • So that would be active folding.

  • And effectively, is there forced unfolding or refolding

  • by GroEL itself?

  • So perhaps the apical domains can

  • force unfolding before polypeptide

  • is released into the chamber.

  • And the cartoon that was just up indicated that to some degree.

  • Maybe the cavity walls are involved.

  • And what I would say is that the pendulum on this

  • has swayed quite a bit over the years in terms of

  • whether or not GroEL is a passive folding cage

  • or actively involved in folding.

  • And some of the debates in the literature

  • have resulted from experimental set-up

  • that may bias results to indicate

  • one thing or the other.

  • And that's something the community is striving

  • to work out these days.

  • And I'll talk about that a bit more on the next slide.

  • But I'll just note-- these questions are still there,

  • and the recent review I just noted

  • discusses these questions.

  • There was a study just a few years ago

  • that was performed with very dilute polypeptide substrate--

  • so below one nanomolar.

  • And what they conclude from this study

  • is that GroEL is involved in active folding

  • of a maltose-binding protein mutant.

  • One question I'll just spring up with this

  • is, maltose-binding protein is a nice model polypeptide,

  • but what happens for a native GroEL substrate?

  • And is there utility in studying those?

  • So why have I emphasized this dilute protein sample point

  • here?

  • So what happened in some early work,

  • in terms of studies that were done to try to differentiate

  • active or passive folding, is that there

  • were some complexities in in vitro studies.

  • So, here, I just have a cartoon of folding in the chamber.

  • And if we think about only one polypeptide within the GroEL

  • chamber, it's folding in isolation.

  • So there's no possibility for it to form

  • an aggregate or a ligamer with other polypeptides.

  • It's all alone here.

  • So this folding in the chamber avoids the complications

  • of the folding landscape we talked

  • about in the introductory lecture to this module.

  • So what happens in aqueous solution, right?

  • There's the possibility that, depending on your conditions,

  • maybe there's some sort of aggregate that forms.

  • And if this aggregate forms, what does that

  • mean in terms of what you see?

  • And so, in earlier work, there were

  • some in vitro kinetic studies that

  • indicated GroEL accelerates folding relative to folding

  • in dilute aqueous solution.

  • But some of these comparisons weren't appropriate,

  • because as it turns out, oligomerization might compete

  • with what you're watching for.

  • And so, if there's some oligomerization happening,

  • it might indicate that the rate is slower than you think.

  • So there's ways to monitor for this.

  • And it's just a point in terms of what control studies do

  • you need to do to make sure your experimental setup is

  • appropriate there.

  • I think it'll be exciting to see what's

  • to come in future years about this question

  • and what kinds of biophysical techniques

  • are applied, including single-molecule studies here.

  • So where we're going to go, moving on,

  • is to think about what actually are the substrates for GroEL.

  • So what polypeptides get folded in this chamber?

  • And how do we begin to address that question

  • from the standpoint of what's happening in the cell?

  • OK, so first, we're just going to consider some observations.

  • And then we're going to go into the experiments here.

  • So here are some observations.

  • So the first one is that polypeptides,

  • up to 60 kilodaltons, can fold in this chamber.

  • So that's quite big--

  • 60 kilodaltons.

  • Some proteins or polypeptides need

  • to enter the GroEL multiple times to be folded.

  • So that means the chaperone has the ability to bind and release

  • and re-bind the polypeptide here.

  • So when studies are done in vitro, what's found

  • is that almost all polypeptides interact with GroEL.

  • So you just saw even an example of that

  • in terms of this non-native maltose-binding protein.

  • So many polypeptides will interact.

  • And this really contrasts what's observed in the cell,

  • where, in vivo GroEL is involved in only folding about 10% of E.

  • coli proteins here.

  • OK, so what observations three and four suggest

  • is that GroEL has some preference

  • for particular endogenous polypeptides.

  • And what we want to answer is, what are these polypeptides,

  • and what are their properties here?

  • OK, so Hartl's group did some nice studies

  • to look at this, what needs to be done.

  • First of all, there needs to be a way

  • to isolate the polypeptides that are interacting

  • with GroEL in the cell.

  • And then, once these polypeptides are isolated,

  • they need to be analyzed in order

  • to learn about their identity and properties.

  • OK, so we're going to look at experiments

  • that were done to address this.

  • And they involve pulse-chase labeling

  • of newly synthesized proteins, amino precipitation,

  • and analysis here.

  • So in terms of addressing what are these substrates,

  • we're going to begin with pulse-chase labeling.

  • OK, so basically, the goal of this experiment

  • and why we're starting here is we

  • want to determine which proteins interact with GroEL.

  • And, in addition to which proteins,

  • we want to determine how long they interact.

  • OK, so what is the experiment?

  • These experiments are going to be

  • done with like E. coli cells.

  • So we want to know what's happening in the cell.

  • So imagine we have an E. coli.

  • And so these bacteria are grown in some culture medium.

  • And the trick here is that they're

  • going to be grown in medium that's depleted in methionine.

  • So incubate, or grow, in medium with no methionine.

  • OK, so effectively, we're depleting them

  • of that amino acid.

  • OK, so then after some period of growth,

  • what are we going to do?

  • We're going to spike the culture with radiolabeled methionine.

  • And this is the pulse.

  • So we're going to add 35S methionine.

  • And we're then going to incubate for 15 seconds.

  • OK, and so that's the pulse with a radiolabeled amino acid.

  • Then what are we going to do?

  • And after we go through the steps, we'll go through why.

  • After this stage, we're going to add

  • excess unlabeled methionine.

  • And we're going to then continue this culture for 10 minutes.

  • OK, this is the chase here.

  • And during this chase period, basically, samples

  • will be taken at varying time points.

  • OK, and then, at some point, we're just going to stop this.

  • OK, so just say, stop culture and experiment.

  • So what's happening in each of these steps?

  • And why are we doing this?

  • So what we want to do is think about newly translated

  • polypeptides.

  • OK, so we have a living E. coli.

  • It has ribosomes.

  • And these ribosomes are going to be synthesizing polypeptides

  • over the course of this experiment.

  • So during the pulse period, all proteins, or all polypeptides,

  • synthesized are radiolabeled.

  • Right, because the methionine has been depleted

  • from the culture medium.

  • And so effectively, the methionine

  • that these organisms are seeing are the S35-labeled methionine.

  • And all polypeptides have an informal methionine

  • from the initiator tRNA and what other methionines

  • are in the sequence.

  • So, if we think about doing this for 15 seconds,

  • and we think about the translation rate, which

  • I gave as 6 to 20 amino acids per second

  • when we were discussing the ribosome,

  • we want to think about how long are these polypeptides going

  • to be?

  • So we have a translation rate of 6 to 20 amino acids per second.

  • OK, so, if we think about 15 seconds of a pulse,

  • we're getting polypeptides on the order

  • of 90 to 300 amino acids synthesized during that time.

  • So newly synthesized polypeptides in these 15

  • seconds are radiolabeled.

  • What happens next?

  • OK, we have this chase period where we flood the system

  • with unlabeled methionine here.

  • Why are we doing this?

  • So certainly, there are some polypeptides

  • that are longer than 300 amino acids that still need time

  • to be synthesized.

  • And if there's new peptides being synthesized

  • that start in this stage, we won't see them,

  • because this unlabeled methionine

  • is in vast access over the radiolabeled methionine that

  • was added early.

  • So here, we have, the synthesis of larger polypeptides

  • can be completed.

  • And we have, no longer producing radiolabeled new peptides.

  • OK, so this allows us to only see

  • the peptides that were radiolabeled during this pulse

  • period here.

  • So what are we going to do in terms

  • of the sampling at various time points?

  • So let's say we want to sample at one minute, five minutes,

  • ten minutes.

  • What do we need to do?

  • So can we just aliquot some of these E. coli

  • and put them on our bench?

  • We could, but that's not going to be very helpful to us,

  • because what we want to do is stop the translation

  • machinery and all of the cellular machinery here.

  • AUDIENCE: You need some kind of clench?

  • ELIZABETH NOLAN: Yeah, we need a clench.

  • And not only do we need a clench,

  • we're dealing with a living organism too, right?

  • So we need to break open the E. coli in whatever this condition

  • is to stop the reaction.

  • OK, so we're going to take aliquots

  • at varying time points.

  • And basically, we care about time,

  • so you have to immediately lyse, or break open, the cells.

  • And this was done in the presence of EDTA.

  • So what is EDTA?

  • AUDIENCE: Ethylenediaminetetraacetic

  • acid.

  • ELIZABETH NOLAN: Yeah, ethylenediaminetetraacetic

  • acid.

  • So it's the chelator.

  • And why might this lysis be done in the presence of this metal

  • chelator?

  • AUDIENCE: [INAUDIBLE] processes like--

  • [INAUDIBLE] magnesium, which would help [INAUDIBLE]

  • AUDIENCE: Are the proteases that are not binding?

  • ELIZABETH NOLAN: There certainly are zinc proteases.

  • So that that's one class of protease.

  • So EDTA will chelate many, many different metals.

  • The main point here is we want to stop stop translation,

  • shut down processes here.

  • OK, so we have these samples.

  • What do we need to do next?

  • We need to detect these newly synthesized proteins that

  • interact with GroEL.

  • And we want to do this at each time point.

  • So how are we going to do this?

  • We have a very complex mixture that has

  • all of the cellular components.

  • So the next step in this will be immunoprecipitation.

  • And so, what will happen in immunoprecipitation

  • in these experiments is that the researchers had an antibody

  • that binds to GroEL.

  • And this antibody was put on a bead

  • and used to fish out GroEL from this complex mixture.

  • And we need to talk about these antibodies a little more.

  • But just in starting, I imagine there's a bead.

  • And we think about antibodies as being Y-shaped biomolecules.

  • So here, we have a GroEL.

  • And imagine that, in this mixture,

  • we have GroEL that has some polypeptide bound.

  • That's one of its endogenous substrates.

  • So, if these are mixed together, then the antibody

  • binds GroEL with the polypeptide attached.

  • OK, here, we can imagine "capture" of this species

  • here and using the bead to separate, say,

  • by centrifugation.

  • So let's think about this a little bit

  • and a little background to have everyone up to speed.

  • If you need to learn more about antibodies,

  • please see a basic biology textbook for further details.

  • But these are Y-shaped molecules that

  • are produced by a type of immune cell called B cells.

  • And they're used by the immune system

  • to detect foreign biomolecules and help to neutralize them.

  • And so, in these, the tip of the Y

  • contains the paratope that ideally binds specifically

  • to a particular epitope-- in this case, GroEL here.

  • And so, we often think about a lock-and-key model

  • with antibody and think about the antibody binding its target

  • with precision here.

  • So for these experiments that were done,

  • just realize the researchers had to come up

  • with an antibody to GroEL.

  • How is that done?

  • They may have immunized, say, a rabbit

  • or given a rabbit GroEL and allowed that rabbit

  • to produce antibodies.

  • And then they isolate the antibodies here.

  • So something we want you to take home from this course

  • is, yes, the antibodies should bind the target with precision.

  • But there's huge problems in terms of use

  • of antibodies in research.

  • This is just the start of an article that was published

  • last year around this time.

  • And it's focused on pharma and clinical trials.

  • But this is much more broad.

  • And often, antibodies aren't as specific as indicated

  • by the label on the container from the supplier here.

  • And it's pretty dismal what they quote

  • in this terms of how difficult it is to reproduce data here.

  • So if you're going to use an antibody,

  • you always need to test it to see whether it is selective

  • or not for the species of interest

  • that you want to detect there and have

  • that information on hand so you don't misinterpret your data

  • here for that.

  • So what are the steps for this immunoprecipitation?

  • Basically, as shown on the board,

  • beads will be functionalized with the antibody

  • and then just added to the cell lysate.

  • And the antibody can recognize GroEL.

  • And the goal and hope are that whatever

  • polypeptides are associated with GroEL are pulled down together.

  • So that's something a bit incredible

  • here that these polypeptides remain bound to GroEL

  • during the steps of this process.

  • You can imagine, if there's a low-affinity binder,

  • it could be lost.

  • So the sample can be centrifuged.

  • And then, you can isolate these beads here.

  • So, in cartoon form, a complex cell

  • lysate in your microcentrifuge tube.

  • You can add the antibody, centrifuge.

  • And see, down here, we've pelleted the beads

  • with GroEL attached.

  • And then some sort of workup needs

  • to be done to dissociate the protein, or polypeptide,

  • substrates here.

  • And then they can be analyzed.

  • AUDIENCE: How long do they do that for?

  • Do you know how many--

  • ELIZABETH NOLAN: How long do they centrifuge for?

  • AUDIENCE: No, for the immunoprecipitation.

  • Is it 30 minutes?

  • Is it--

  • ELIZABETH NOLAN: I don't know how long the incubation

  • time is.

  • Need to go back to the experimental,

  • but that's getting right back to this question as to how

  • do they stay bound.

  • AUDIENCE: How do they stay bound?

  • ELIZABETH NOLAN: Yeah.

  • So, see the point here.

  • If you have a high-affinity complex, that's one thing.

  • If you have low-affinity association between GroEL

  • and the polypeptide, you can imagine

  • it might get lost during this workup.

  • And how much do we know about those affinities there?

  • AUDIENCE: You said that they would just give rabbits GroEL,

  • and hopefully antibodies would just happen.

  • But if a rabbit's immune system encountered GroEL,

  • would it actually see it as an antigen

  • that it had to develop antibodies against?

  • ELIZABETH NOLAN: So, yeah.

  • So here's the point--

  • would it?

  • So, if it's E. coli GroEL, would the rabbit recognize this,

  • yes or no?

  • And if no, then what can you do to provoke an antibody

  • response?

  • And so, what can be done is, say,

  • you could take a GroEL subunit and attach that

  • to something immunogenic.

  • So there are carrier proteins that

  • will mount an immune response.

  • So one of the subunits of cholera toxin

  • is an example that can be used.

  • And then the idea is you're mounting an immune response

  • against that carrier protein.

  • But you'll also get antibodies to whatever is attached.

  • So that's another strategy for doing it

  • if direct injection doesn't work.

  • And too, not going off on a big tangent,

  • but there are some decisions that need to be made.

  • So would they use the full-length GroEL?

  • Or maybe they would just use a polypeptide region,

  • like some shorter polypeptide that's a portion of GroEL.

  • So there's a lot of possibilities

  • there in terms of what you use to generate

  • the antibody for that there.

  • And it's something that a lot of companies do these days.

  • You can send them your protein or your polypeptide fragment.

  • And they'll conjugate it to one of these carriers

  • and treat the rabbits or whatever animal

  • and then isolate those antibodies.

  • And then they need to be characterized there for that.

  • OK, so how are these samples going to be analyzed?

  • That's the next step.

  • So, for the analysis, effectively, we're

  • going to have some mixture.

  • And, at the onset, we don't really

  • know how complicated this mixture will be.

  • I told you initially that about 10% of E. coli polypeptides

  • are thought to be substrates for GroEL, which

  • is quite a large number if we think about the total number

  • of proteins in E. coli.

  • And the other point is we have this radiolabel, which

  • we're going to use for detection there.

  • OK, so, for analysis--

  • OK, there's two things.

  • We need to separate these various polypeptides

  • in each sample.

  • And then we need to determine what their identities are here.

  • So-- that were bound to GroEL from one another.

  • OK, and then, we need to determine identities.

  • And once we know the identities, we

  • can think about their properties.

  • And this needs to be done in every sample that was collected

  • along this time course, which is also going to give

  • some temporal information.

  • So what are the methods that have been used?

  • So, in order to separate the proteins in this complex

  • sample, the method is a 2-D gel--

  • so 2-D gel electrophoresis.

  • OK, and in terms of determining the identities, what's

  • done, once these polypeptides are separated,

  • is to do a protease digest and then mass spectrometry.

  • Has anyone here ever run a 2-D gel or seen the equipment?

  • One person.

  • Has anyone heard of 2-D gels?

  • Fair number.

  • OK, so, we'll go over this briefly in terms of 2-D gel.

  • So, in terms of 2-D gel electrophoresis,

  • we talk about running these gels in two dimensions.

  • And, in each dimension, we separate

  • based on a different property.

  • So, in the first dimension, the separation is based on charge.

  • And effectively, we can talk about the pI of a protein.

  • So the pI is the isoelectric point.

  • And it's the pH where the net charge on the protein is zero.

  • And so, the type of gel we use here

  • is called isoelectric focusing, or IEF.

  • And effectively, what's done is that the gel electrophoresis is

  • done through a continuous and stable pH gradient.

  • And, in this gel, the protein will migrate to a position

  • where the pH corresponds to the pI.

  • Then the anode is low pH and the cathode high pH.

  • So that's quite different than SDS, where, in an SDS-PAGE gel,

  • we're coating the protein with negative charge.

  • So then, the second dimension is something most of us

  • are familiar with, is SDS-PAGE.

  • And so, what happens in SDS-PAGE?

  • We have separation based on size here--

  • on molecular weight.

  • So has anyone not run an SDS-PAGE gel?

  • And this is totally fine.

  • I never ran one till I was a postdoc.

  • So it's not something to be ashamed about if you haven't.

  • OK, so everyone has.

  • So what's the ratio of SDS molecules to amino acids?

  • So if you take your protein sample

  • and you put it in your loading buffer and run your SDS-PAGE,

  • what is the ratio of binding?

  • What is SDS?

  • AUDIENCE: Sodium dodecyl sulfate.

  • ELIZABETH NOLAN: And what does it do?

  • What happens to your protein in SDS?

  • AUDIENCE: Denatures it.

  • ELIZABETH NOLAN: OK, what else?

  • So it's a denaturant.

  • So it denatures the protein.

  • So why does SDS-PAGE let you separate

  • based on molecular weight, more or less?

  • AUDIENCE: It coats the protein, more or less,

  • uniformly with negative charge.

  • ELIZABETH NOLAN: Yeah.

  • AUDIENCE: Do we know the exact ratio of binding?

  • ELIZABETH NOLAN: Yeah, so what's the ratio of binding

  • that can be done in terms of grams

  • of SDS per grams of protein or number of SDS

  • molecules per amino acid.

  • What is it?

  • And there'll be some error, but there's approximates.

  • But it's something to think about, right?

  • You're putting your sample into this.

  • So it's about 1.4 grams of SDS per gram of protein.

  • That's the ratio there.

  • And as said, the idea is that SDS is giving the protein

  • a large net negative charge.

  • So it's going to override whatever the intrinsic charge

  • is of the protein.

  • And so, it gives all proteins a similar mass-to-charge ratio

  • here.

  • With that said, sometimes, there are

  • proteins that migrate in the gel in a manner that's

  • not reflective of their molecular weight.

  • That's just something to keep an eye out on.

  • So within the slides that will be posted on Stellar,

  • there'll be some background information

  • about both of these methods--

  • the IEF gel and SDS-PAGE, which I

  • encourage you to take a look there.

  • OK, so back to the 2-D gel--

  • how is this actually going to be run?

  • So it's one gel.

  • First, it needs to run the IEF gel.

  • And you need a special apparatus for.

  • This it's called a cylinder, or tube, gel--

  • so not flat like what you're all accustomed to for SDS-PAGE.

  • Then, this gel needs to be equilibrated in the SDS-PAGE

  • buffer.

  • And then, you run the SDS-PAGE separation.

  • And, in this step, just to note, the gel is rotated 90 degrees.

  • OK, so what you get--

  • you get a gel where we have molecular weight here.

  • We have pI here.

  • And if it's a cell lysate, there's

  • going to be many, many spots.

  • These should all be spots unless you

  • did a poor job running the gel.

  • So this 2-D gel is being used, because it's

  • going to provide better separation than a standard 1-D

  • gel.

  • Imagine trying to separate peptides out of some cell

  • lysate using just a 1-D gel.

  • Even after this immunoprecipitation,

  • we'll see that these samples are very complicated here for that.

  • So what we need is some way to detect the spots that indicate

  • different polypeptides.

  • So what are methods?

  • Maybe Coomassie stain for total protein.

  • We can use the radiolabel--

  • autoradiography, for instance, which is what's done here.

  • We're looking at the S35 radiolabel--

  • or maybe Western blot here.

  • So how are we going to get from this gel

  • to knowing the identity of each of these spots?

  • AUDIENCE: You have to identify your spot,

  • excise it, extract the protein from the gel,

  • adjust it, and then run NS and line it up

  • with known protein for evidence.

  • ELIZABETH NOLAN: Exactly.

  • So what will be done is that each spot of interest

  • will be cut out of the gel.

  • So you need a way to mark them.

  • You'll see they're numbered in the data that we'll look at.

  • The protein needs to be extracted out of the gel.

  • Then the protein will be incubated

  • with a protease that will give some number of fragments.

  • Trypsin was used in this work.

  • And then that digest can be analyzed by mass spec.

  • And so, for each sample, you get all of the m over z values

  • for the different polypeptides that resulted from the digest.

  • And then, effectively, you can compare that

  • to some database of E. coli protein sequences.

  • So further details are provided throughout here.

  • So what are the major questions?

  • And what are we going to look for answers for in the data

  • here?

  • So first, how many proteins interact with GroEL?

  • We can imagine getting an answer to this

  • by counting the number of spots.

  • What are the identities and structural features

  • and properties of the proteins that interact with GroEL?

  • We're going to get that from the mass spec analysis and then

  • literature studies.

  • And then another question we can get at is asking,

  • how long do proteins interact with GroEL?

  • Because we're calling the pulse-chase samples

  • were taken at various time points

  • over that 10-minute period.

  • So, at two minutes, do we see the same polypeptides

  • associated as we see at 10 minutes?

  • Or if we monitor one given polypeptide,

  • when does it show up and potentially

  • disappear from the gels?

  • So all of these samples can be addressed with these methods.

  • And where we'll begin on Friday is

  • going through the data in some detail.

  • But just as a prelude to that in the last minute,

  • here's the data from the paper for these gels.

  • So this is looking at the 2-D gels for, on the top,

  • total soluble cytoplasmic proteins at zero minutes

  • and then total cytoplasmic proteins at 10 minutes.

  • So this is without the immunoprecipitation.

  • And then, at the bottom here, what we're looking at

  • are the polypeptides that we're isolated

  • from the immunoprecipitation with the anti-GroEL antibody

  • at zero minutes and 10 minutes.

  • And so, before we meet next time,

  • what I encourage you to do is take a close look at these gels

  • and see what information can you pull out just

  • from a qualitative look.

  • So simple questions, like, we see a lot of proteins here.

  • And please don't go and try and count all the spots.

  • I'll give you the numbers next time.

  • How do these gels here from the immunoprecipitation

  • differ from these up top?

  • And it's not just the total number of proteins.

  • There's some additional subtleties in these data.

  • OK, so next time we'll begin examining these data,

  • looking at what polypeptides were pulled down.

  • And then we'll move into looking at the chaperone DnaK,

  • DnaKJ system there.

The following content is provided under a Creative

Subtitles and vocabulary

Click the word to look it up Click the word to find further inforamtion about it